Press What’s news at AbelsonTaylor Group
Select category
Moving Into 2024
Applying his background in pharmacology, Jeff Berg, President of AbelsonTaylor Group, discusses a particularly exciting use of AI in drug discovery that is tackling one of biology’s biggest challenges – predicting the 3D shape of proteins and designing them from scratch. Read more at https://www.pharmalive.com/healthcare-agency-roundtable-2024-moving-into-2025/
Media Contact:
Recent Posts
The biggest barrier to AI adoption in healthcare isn’t regulation. It’s trust.
As AI adoption accelerates, trust may be the real differentiator. In MedAdNews, Janet Barker-Evans, Chief Creative Officer of AbelsonTaylor Group,...
In the News Read more The biggest barrier to AI adoption in healthcare isn’t regulation. It’s trust.From Insights to Action: The Bridge Between Strategy and Execution
“Having access to more information doesn’t automatically lead to better decisions—you need judgment,” says AbelsonTaylor Group’s Amy Restko, VP, Engagement...
In the News Read more From Insights to Action: The Bridge Between Strategy and ExecutionRob Chartier Joins AbelsonTaylor Group as Director of Engagement Strategy
AbelsonTaylor Group today announced that Rob Chartier has joined the agency as Director of Engagement Strategy. Chartier brings more than...
Read Press Read more Rob Chartier Joins AbelsonTaylor Group as Director of Engagement StrategyConnect with us
Find out what's top of mind for the people reimagining health and wellness advertising.